Skip to search formSkip to main contentSkip to account menu

carvedilol phosphate

The phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and devoid of intrinsic… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The objective of the present study was to design and evaluate once daily sustained release tablet of carvedilol, using two… 
2016
2016
  • 石磊
  • 2016
  • Corpus ID: 104554100
The invention provides a preparation method of carvedilol phosphate hemihydrates. The preparation method comprises the following… 
2013
2013
Article history: The aim of this present work was to develop and optimize compression coated tablet of carvedilol sulphate for… 
2012
2012
Controlled porosity osmotic tablet of carvedilol phosphate prepared and evaluated in this study. Carvedilol phosphate is very low… 
2011
2011
UNLABELLED A 3(2) full factorial design was employed for the formulation and characterization of an expandable, gastroretentive… 
2011
2011
Objectives  Lipid nanoparticles as carrier for oral drug administration improve gastrointestinal solubility of poorly soluble… 
2011
2011
Controlled porosity osmotic pump tablets loaded with carvedilol phosphate, a BCS class II drug has been successfully designed and… 
2011
2011
β-adrenergic blocking agents have been in use for nearly 40 years. β-blockers have been more thoroughly studied in the past… 
2003
2003
本発明は、リン酸二水素カルベジロール(すなわち、1−(カルバゾール−4−イルオキシ−3−[[2−(o−メトキシフェノキシ)エチル]アミノ]−2−プロパノール)および/またはリン酸水素カルベジロールのリン酸二水素塩等)および/またはその溶媒和物の新規結晶性形状を含むカルベジロールリン酸塩、前記塩および/または溶媒和物を含む組成物、ならびに高血圧、鬱血性心不全および狭心症等を治療するための前記塩および/または溶媒和物の使用方法に関する。